Jason K Garland, chief financial officer of US-based bioprocessing firm Repligen Corporation, has sold $79,500 worth of company stock, according to a filing with the Securities and Exchange Commission. The transaction, which took place earlier this month, involved the sale of a limited number of shares at prevailing market prices.
Insider sales at Repligen are closely watched by UK fund managers given the company's prominence in the life sciences supply chain. While the sale represents only a small fraction of Garland's total beneficial ownership, it comes at a time when the broader bioprocessing sector is grappling with reduced capital expenditure from pharmaceutical clients.
Repligen's share price has declined by approximately 12% since the start of 2026, underperforming the S&P 500. The company, which supplies single-use technologies for drug manufacturing, has faced headwinds as major drugmakers scale back post-pandemic capacity expansion. UK pension funds and investment trusts with exposure to US healthcare equities have felt the ripple effects.
Analysts at RBC Capital Markets recently noted that bioprocessing demand may not recover until late 2027, citing destocking by large customers. For UK investors, the sector's struggles have weighed on the performance of life sciences-focused funds, though some see the current valuation as a potential entry point.
The CFO's sale is unlikely to trigger alarm, as insider transactions at this level are often part of routine financial planning. However, it adds to a pattern of insider selling at Repligen over the past six months, with three other executives also reducing their positions.